https://www.oncologynurseadvisor.com Tue, 19 Dec 2023 16:02:08 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/genitourinary-cancer/upper-tract-urothelial-carcinoma-utuc-neoadjuvant-chemotherapy-before-surgery-improves-outcomes/ Tue, 19 Dec 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=114556 Latest findings are from one of the largest experiences of neoadjuvant chemotherapy in upper tract urothelial carcinoma to date.]]> https://www.oncologynurseadvisor.com/home/cancer-types/genitourinary-cancer/gemcitabine-docetaxel-may-be-a-feasible-alternative-to-bcg-for-high-risk-nmibc/ Fri, 15 Dec 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=114560 Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/genitourinary-cancer/radical-cystectomy-added-to-chemotherapy-ups-survival-in-cn1-bladder-cancer/ Fri, 15 Dec 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=114568 Investigators report a 46% lower risk for death compared with chemotherapy alone.]]> https://www.oncologynurseadvisor.com/home/cancer-types/kidney-cancer/partial-nephrectomy-may-be-an-option-for-t3a-renal-cell-carcinoma/ Wed, 13 Dec 2023 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=114564 Partial and radical nephrectomy for T3a RCC have similar 5-year rates of overall and cancer-specific survival, according to a propensity score-matched analysis.]]> https://www.oncologynurseadvisor.com/home/cancer-types/genitourinary-cancer/nmibc-recurrence-common-despite-complete-response-to-mibc-neoadjuvant-chemotherapy/ Wed, 06 Dec 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=114562 Patients who experienced NMIBC recurrence were not at higher risk to recur with muscle-invasive or metastatic disease.]]> https://www.oncologynurseadvisor.com/home/cancer-types/prostate-cancer/prostate-mri-misses-nearly-one-quarter-of-clinically-significant-prostate-cancers/ Wed, 06 Dec 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=114548 Real-world data demonstrate that multiparametric MRI has a lower negative predictive value than previously reported.]]> https://www.oncologynurseadvisor.com/home/cancer-types/prostate-cancer/real-world-data-confirm-efficacy-of-177lutetium-psma-617-for-mcrpc/ Thu, 07 Sep 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=110206 A PSA decrease of 30% or more occurred in 77.8% of patients after the third treatment cycle, investigators report.]]> https://www.oncologynurseadvisor.com/home/cancer-types/kidney-cancer/lymphovascular-invasion-ups-mortality-risk-in-kidney-cancer-surgery-cases/ Tue, 05 Sep 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=110141 Investigators believe their study is the first to demonstrate the adverse impact of LVI on overall survival in patients with surgically treated renal cell carcinoma.]]> https://www.oncologynurseadvisor.com/home/cancer-types/genitourinary-cancer/erdafitinib-cetrelimab-metastatic-urothelial-carcinoma-elicits-durable-responses/ Thu, 22 Jun 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=108672 Erdafitinib alone or in combination with cetrelimab has shown activity in a phase 2 trial of patients with FGFR-altered metastatic urothelial carcinoma.]]> https://www.oncologynurseadvisor.com/home/cancer-types/prostate-cancer/talazoparib-enzalutamide-mcrpc-hrr-mutations-beneficial/ Tue, 06 Jun 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=108169 Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests. ]]>